We are excited to announce that Eagle IP will be participating as a sponsor and exhibitor at the upcoming Life Sciences Patent Network (LSPN) North America Fall Conference in San Francisco. Our President and Managing Director, Ms. Jennifer Che, is a distinguished speaker at the event. Her talk, titled China Patent Landscape, will provide a brief overview of top China IP issues for life sciences companies and provide some strategies for how to navigate such issues (e.g., AI, post-filing data, PTA/PTE, patent linkage, export controls, and more).

Organized by Life Sciences Intellectual Property Review, this event will take place October 21-22, 2025.


Eagle IP will also be in the greater Washington DC area from October 27-31, 2025. Ms. Jennifer Che will be attending Life Sciences Masters™ 2025 (organized by IP Watchdog) in Ashburn, Virginia from October 27-29, and AIPLA 2025 Annual Meeting (organized by American Intellectual Property Law Association) in Washington DC from Oct 29-31.

If you won’t be able to attend LSPN or AIPLA, but will be in San Francisco or the Washington DC area and would like to schedule a meeting, please let us know. We look forward to seeing some of you in San Francisco and Washington DC later this month!

Our Past Events

Recommended Insights

Amendments to the China Patent Examination Guidelines in 2022 - Part 1: New rules for designs in view of China signing onto the Hague Agreement

2 December 2022
This year, China stepped further onto the international scene by signing on as a member of the Hague Agreement. The Hague Agreement is an international registration system allowing applicants to file a single international design application in a single language to obtain protection in over 100 designated member countries. The US has been a member […]

CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants

12 April 2023
At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines1 (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]

Thin Disclosure but "Bulletproof" Protection: How a Salt Form Patent was Upheld in China Despite Minimal Data

8 January 2026
In China, innovative drug companies typically rely on their initial composition of matter patents to block out competitors. Other “follow-on” IP, such as those directed towards formulations, polymorphs, and salt forms, are often regarded as less likely to survive invalidation challenges, especially in China where the standard of “person skilled in the art” is so […]

First Ever Successful Invalidation Challenge Due to Unauthorized Foreign Filing

8 March 2023
What does an invention “completed” in China mean? China and the US are similar in that both countries highly value national security, and thus have rules regulating the exportation of technology and information from within their borders. This includes new inventions that arise from within their respective borders. As such, both governments require inventors who […]
Top crossarrow-right